IBA, a spin-off company of UCL established in 1986, has become the world leader in proton therapy by developing its expertise in particle accelerators for cancer treatment. IBA, UCL (Pr B. Macq, ICTEAM/ELLEN) and Pr J. Lee (IREC/MIRO) and the Walloon Region teamed up in 2011, establishing the iMagX team, with a view to developing innovative imaging solutions to improve the accuracy of proton therapy.

Consequently, iMagX was launched as part of a public-private partnership, which ended in September 2015. So, 25 years after its creation, IBA has returned to its home university with some pioneering challenges that have enabled the UCL teams and IBA to achieve a world premiere: the first proton therapy guided by volumetric imaging in the treatment room at the University of Pennsylvania in Philadelphia.

**Date of licence agreement**

“Proof of Concept” Grant

Research project beginning

**September 2015**

**2013**

**2011**